This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 26 March 2024; doi:10.1038/s41569-024-00997-0 In this Review, Bozkurt provides an overview of the management of patients with heart failure across the full range of left ventricular ejection fraction, derived from the recommendations in the latest US and European guidelines.
This scientific statement discusses the mechanism of arrhythmias, pharmacological treatment options, and distinct aspects of pharmacokinetics for the fetus and neonate.
Hence, to date, no single pharmacological option exists to treat them. Genetic modification in a mouse model of IAs, including deletion or overexpression of a particular gene, provides an excellent means for examining basic mechanisms behind disease pathophysiology and developing novel pharmacological approaches.
The available evidence on the impact of specific non-pharmacological interventions on glycaemic control is currently limited. Consequently, there is a need to determine which interventions could provide the mo.
Various pharmacological and non-pharmacological methods are available t. Removing the chest tube in cardiac patients after surgery is one of the worst experiences of hospitalization in the intensive care units.
A key opinion leaders explore effective non-pharmacological therapies and lifestyle modifications that have shown significant promise in managing fibromyalgia symptoms, complementing traditional medication-based approaches.
The following are key points to remember about a clinical guideline from the American College of Physicians (ACP) on newer pharmacologic treatments in adults with type 2 diabetes.
22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics. GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug.
3 Should we continue with a conservative, stepwise approach, beginning with pharmacological management and delaying intervention until MR severity worsens? 2 As the clinical understanding of SMR evolves, so too does the debate over the optimal treatment strategy.
In this narrative review, we discuss the pathophysiology of CS, novel phenotypes, evolving definitions and staging systems, currently available pharmacologic and device-based therapies, standardized, team-based management protocols, and regionalized systems-of-care aimed at improving shock outcomes.
Preventive Services Task Force (USPSTF) plans to recommend intensive behavioral interventions -- but not pharmacologic therapies -- for kids with a high body mass index (BMI). (MedPage Today) -- The U.S. In its draft recommendation statement.
Optimal pharmacological and non-pharmacological management (including device treatment) have had an enormous beneficial impact on the clinical course of HF. This module will focus on lifestyle modifications and pharmacological treatment.
The primary electrophysiological mechanism of atrial fibrillation (AF) maintenance is poorly defined. AF mapping studies readily record focal activations (defining them as focal sources or breakthroughs) and incomplete reentries (defining them as reentries or would-be-reentries) but do not or rarely detect complete circular activations.
Here we tested our hypothesis that pharmacological inhibition of TGFR2 in mice models of dementia may reduce RTN gliosis, breathing disorder and cognitive impairment.We TGFR2 pharmacological inhibition additionally reduced astrogliosis in the RTN of Tg-2576 mice (drug 53.624.8 vs. 58.25.16, p=.03 03 n=7/group) and NORT (59.13.28
Results Pharmacological/non-pharmacological secondary prevention methods have been efficiently applied. Baseline aggregometry indicated platelet hyperactivity, decreasing gradually and being significantly reduced late, at 12 months ( p < 0.05).
Pharmacologic CTH inhibition suppressed glioblastoma invasion, while CTH knockdown slowed glioblastoma invasion in vivo. A CRISPR metabolic gene screen revealed cystathionine γ-lyase (CTH), which converts cystathionine to the nonessential amino acid cysteine in the transsulfuration pathway, to be essential for glioblastoma invasion.
A variety of technologies, including network pharmacology, RNA-sequencing, immunohistochemistry, and Western blotting were performed to investigate its underlying mechanisms.
This substudy of the Danish-German (DanGer) Shock randomized clinical trial investigates if the use of a microaxial flow pump reduces the need for pharmacological support and what the effects are on hemodynamics and lactate clearance in patients with ST-elevation myocardial infarction–induced cardiogenic shock.
Together, these findings offer critical insights into the functional role of LSGLP-1R neurons in the physiological regulation of energy homeostasis and delineate their instrumental role in mediating the pharmacological efficacy of liraglutide.
Here, we use large-scale omics data to explore whether pharmacologic targeting of the adiponectin pathway may contribute to lowering CVD risk.Methods:To proxy the effect of pharmacologically perturbing the adiponectin pathway we used a drug-target mendelian randomization (MR) approach. We selected genome-wide, independent (r2<0.1)
Jennifer Goldman, RPh, PharmD, discusses how the pharmacologic advancements in recent years have shifted discussion around lipid, and cardiovascular risk, management in diabetes.
Optional Pre-conference Workshop to be held Friday afternoon includes a number of topics: Pharmacology 101 Pharmacology 101 – Workshop: Alana Ferrari, PharmD, BCOP How Do I Grow My Career in Cardio-Oncology? An overview of sessions, focus topics and presenters follows. Friday, February 9 Registration (1:00 - 6:00 p.m.)
Pharmacological inhibition of EGFR or downstream ER stress may be a promising therapeutic strategy for preventing aneurysm rupture and subarachnoid hemorrhage.
A research team in the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), found that hip fractures not only result in both physical and psychological injuries, but may also induce adverse cardiovascular events.
This review delves into the current therapeutic strategies for CTEPH, including surgical pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and targeted pharmacological treatments such as PDE5 inhibitors, endothelin receptor antagonists, sGC stimulators, and prostanoids.
Genetic and pharmacologic inhibition of BET bromodomain activity reduced DMG cell proliferation and enhanced radiation-induced DNA damage by inhibiting DNA repair pathways. Using high-throughput radiosensitivity screening, we identified bromo- and extraterminal domain (BET) protein inhibitors as potent radiosensitizers in DMG cells.
Importantly, pharmacological blockade of ADORA2A profoundly represses neuroendocrine prostate and lung cancer growth in vivo. Therefore, we believe that ADORA2A can be used as a promising therapeutic target to govern the epigenetic reprogramming in neuroendocrine malignancies.
Emerging approaches, including cellular and gene therapy and novel pharmacologic approaches, are described. Current and emerging approaches to treat cancer therapy–induced dry mouth are presented using radiation-induced salivary dysfunction as a model. Limitations of current sialagogues and salivary analogues are presented.
Nature Reviews Cardiology, Published online: 26 January 2024; doi:10.1038/s41569-023-00986-9 In this Review, Varga and colleagues provide an overview of the evidence on immune checkpoint inhibitor-induced heart failure and cardiac dysfunction that is unrelated to myocarditis, and discuss how pharmacological targeting of immune checkpoints might be (..)
Pharmacological targeting of this receptor with a brain penetrant CB2R inverse agonist/antagonist selectively reduces neuroinflammation without deleteriously affecting systemic GVHD severity.
Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose availability within the tumor microenvironment (TME).
Microneurography showed that central alpha-2 agonists such as clonidine could acutely suppress sympathetic nerve activity (SNA). The acute and long-term neuromodulation effects of clonidine are unknown.
Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate.
Pharmacological prevention of lipid droplet formation reverses the suppression of NO production in cell culture and in vivo and blunts blood pressure elevation in response to a high-fat diet.
The study will compare the safety and efficacy of the Laminar LAAX System to commercially available left atrial appendage (LAA) closure devices, providing a potential non-pharmacologic alternative for eligible patients. This is particularly important for the nearly 40% of AFib patients who cannot tolerate long-term blood thinners3,4.
Despite the existence of well-established risk factors and effective pharmacological treatments for major cardiovascular disease (CVD), these conditions remain among the leading causes of premature death and disability, exerting a substantial burden on health systems worldwide.
The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis provides updated recommendations for the pharmacologic management of RA. In honor of Rheumatoid Arthritis Awareness Day, test your knowledge with this quiz:
In April 1964, leading cardiologists, cardiovascular surgeons, and pathologists convened in London for a 2-day symposium to discuss a relatively new disease entity that we now know as obstructive hypertrophic cardiomyopathy (HCM).1 1 The proceedings kicked off with a comment by the group’s chairman: “I have never before taken.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content